Biocytogen Updates Articles to Reflect STAR Market A-Share Listing and Expanded Capital

The latest announcement is out from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ).

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. plans to amend its articles of association to formally reflect changes in its share capital following the issuance of 47,500,000 A shares and its listing on the STAR Market of the Shanghai Stock Exchange. The amendments specify the updated registered capital of RMB446,898,420 and a total share count of 446,898,420 ordinary shares, aligning the company’s constitutional documents with its expanded capital base.

The board considers the amendments to be in the interests of the company and its shareholders and will seek approval via a special resolution at the upcoming annual general meeting, where votes will be taken by poll. The move underscores Biocytogen’s transition to a dual-listed structure, improving regulatory clarity for investors and strengthening its corporate governance framework across both Hong Kong and mainland China markets.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market, focusing on innovative drug discovery and development. The company operates under a dual-listing structure, reflecting its strategy to access both Hong Kong and mainland China capital markets to support its growth and R&D activities.

Average Trading Volume: 1,913,740

Technical Sentiment Signal: Hold

Current Market Cap: HK$22.61B

Find detailed analytics on 2315 stock on TipRanks’ Stock Analysis page.